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Objective: Suboptimal treatment of chemotherapy-induced nausea and vomiting and unsatis-
factory response to antiemetic drugs cause impairment of cancer patient’s daily functioning.
This study was aimed to investigate the association of selected germline polymorphisms with
ondansetron and metoclopramide response in Indonesian cancer patients treated with highly
emetogenic chemotherapy.
Methods: We enrolled 202 chemotherapy naı¨ve patients treated with cisplatin at a dosage of
50 mg/m2 as monotherapy or as combined chemotherapy. Ondansetron 8 mg and dexa-
methasone 8 mg intravenously were the standard antiemetic therapy for prevention of acute
chemotherapy-induced nausea and vomiting. Metoclopramide 10 mg orally, three times per
day as fixed prescription, was given until 5 days after chemotherapy to prevent delayed
chemotherapy-induced nausea and vomiting. Primary and secondary outcomes were the
occurrence of chemotherapy-induced nausea and vomiting in the acute and delayed phase.
The following single-nucleotide polymorphisms were determined in ABCB1: rs1045642,
rs2032582 and rs1128503; in 5-HT3B-R: rs45460698, rs4938058 and rs7943062; and in
CYP2D6: rs16947 (CYP2D6*2), rs3892097 (CYP2D6*4) and rs1065852 (CYP2D6*10) using
Taqman assays.
Results: During the acute phase, 21.8 and 30.2% patients experienced Grade 3 and 4
nausea and vomiting, respectively, whereas 38.6% patients experienced nausea and/or
vomiting in the delayed phase. Carriers of the CTG haplotype of the ABCB1 gene experi-
enced Grade 3 and 4 chemotherapy-induced nausea and vomiting more often than other
haplotypes in the delayed phase (P, 0.05). No associations were found with the 5-HT3B
receptor haplotypes and CYP2D6-predicted phenotypes.
Conclusions: Our study shows that in Indonesian cancer patients treated with highly
cytostatic emetogenic, carriership of the CTG haplotype of the ABCB1 gene is related to an
increased risk of delayed chemotherapy-induced nausea and vomiting.
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INTRODUCTION
Chemotherapy-induced nausea and vomiting (CINV) is the
most common side effect of cancer patients treated with
highly emetogenic chemotherapy (1) and has a significant
effect on the patients’ daily functioning and well-being (2).
Poor control of acute CINV, which occurs within 24 h after
chemotherapy, may be used as a predictor of delayed CINV
(3). However, patients with delayed CINV, which persists
from 24 to 120 h after chemotherapy, experience more
severe impact of daily functioning than patients with acute
CINV (4).
The introduction of 5-hydroxytriptamine-3 receptor antag-
onists (5-HT3RAs) significantly improved the control of
CINV (4). However, the use of 5-HT3RAs in combination
with dexamethasone as an antiemetic treatment in patients
treated with highly emetogenic chemotherapy provides only
70–80% complete protection in the acute phase (2,6) and
60% complete protection in delayed emesis (5).
Ondansetron is the first 5-HT3RA and the most widely
used in Indonesia community hospitals. Standard antiemetic
treatment for prevention of acute CINV in Indonesia is
ondansetron in combination with dexamethasone. For pre-
vention of delayed CINV, metoclopramide is given orally
from 24 until 120 h after chemotherapy. We realize that the
combination of a 5-HT3RA, a neurokinin 1 antagonist and a
corticosteroid is more effective and is therefore frequently
given to cancer patients treated with high emetogenic che-
motherapy (6,7). This combination increases the complete
protection of acute emesis, with 10–15% increased response
in comparison with the combination of a 5-HT3RA and a
corticosteroid (8,9); currently, the neurokinin 1 antagonist
aprepitant is not available in Indonesia.
Next to the antiemetic treatment regimen, patient charac-
teristics such as age, gender, history of motion sickness and
history of alcohol drinking are known to influence antiemetic
drug efficacy. In addition, in recent years, it appeared that
also genetic variation in genes encoding drug transporters,
metabolic enzymes and drug targets may influence drug
efficacy (3). Indeed, variability in ondansetron transport,
biotransformation and receptor affinity may cause variations
in ondansetron’s efficacy (10). More specifically, ondanse-
tron is transported into the blood–brain barrier by the drug
transporter P-glycoprotein (P-gP) and is partially metab-
olized by, for example, cytochrome P450 2D6 (CYP2D6)
and has moderate affinity on the 5-HT3 receptors (10–12).
In a previous study, it has been reported that the gene
ABCB1-encoding P-gP has a role in the pharmacology of
ondansetron. The ondansetron transepithelial transport
decreased when an inhibiting agent was added into an
MDR1 cell line. In other words, the passive diffusion rate of
ondansetron was increased by P-gP (13). This mechanism
was found in both the gastrointestinal and blood–brain
barrier (11,12). In addition, a polymorphism in the ABCB1
gene, 3435C.T, showed a significant association with the
occurrence of acute CINV in cancer patients (13). Regarding
ondansetron metabolism, it was reported in a Caucasian
population that the ultrarapid metabolizers (UMs) of
CYP2D6 experienced the most severe nausea and vomiting
after chemotherapy treatment (14). It has been shown that
ondansetron is mainly metabolized by CYP1A2, CYP2D6
and CYP3A4 (15). Finally, other studies suggested that vari-
ation of 5-HT3B, 5-HT3C and 5-HTR3D receptors could be
the predictors of 5-HT3RAs’ efficacy in cancer patients
(16–18).
For metoclopramide, gene variations of the protein trans-
porter and the drug-metabolizing enzyme are suggested to
influence efficacy and adverse drug reaction (19,20). The
passage of metoclopramide across the blood–brain barrier is
also influenced by the P-gP transporter (19), whereas its
metabolism is highly dependent on CYP2D6 (20,21).
In theory, not only the response to antiemetic drugs may
be genetically determined but also the susceptibility to eme-
togenic drugs leading to interindividual differences in vomit-
ing and nausea at baseline. However, as our knowledge,
there are no studies relating genetic variants to severity of
chemotherapy-induced emesis. The aim of this study was to
investigate the association of ABCB1, 5-HT3B receptor
polymorphisms and CYP2D6-predicted phenotypes with
ondansetron and metoclopramide antiemetic response of
Indonesian cancer patients treated with highly emetogenic
chemotherapy.
PATIENTS AND METHODS
STUDY POPULATION
The study population involved various cancer patients in the
Oncology Department of Dr Sardjito Hospital, Yogyakarta,
Indonesia, from January 2009 until April 2010, who were
treated with cisplatin at a dosage of 50 mg/m2 as
monotherapy or in combination chemotherapy regimens.
Ondansetron 8 mg and dexamethasone 8 mg intravenously
were the standard antiemetic therapy for prevention of acute
CINV. Metoclopramide, 10 mg orally, three times per day as
fixed prescription, was given to the patients after cytostatic
administration until 5 days after chemotherapy in order to
prevent delayed CINV.
Patients were eligible for this study if they were 18
years old with a Karnofsky performance scale of 50%. We
used self-reported ethnicity. However, to make a more accu-
rate assessment of ethnicity, the ethnicity of the parents and
grandparents also were verified. Exclusion criteria were: the
presence of nausea or vomiting 24 h before chemotherapy;
the use of other antiemetics such as benzodiazepines or
neuroleptics, radiotherapy within 24 h before the start of
chemotherapy; the use of opioids within the last 2 weeks,
the use of inducers of CYP3A4 or inhibitors of CYP2D6;
patients with concomitant diseases that might cause nausea
or vomiting (e.g. ulcerations or obstruction of the upper
gastrointestinal system, aspartate aminotransferase/alanine
aminotransferase .2.5 ULN for patients without liver
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metastases and .5 ULN for patients with liver metastases,
renal dysfunction defined by creatinine clearance ,60 ml/
min, brain metastases, artificial stoma or pregnancy).
This study has been approved by The Ethical Committee
of the Medical Faculty of Universitas Gadjah Mada,
Yogyakarta, Indonesia. All of the patients signed the consent
form before enrollment.
NAUSEA AND VOMITING ASSESSMENT
Every patient completed a daily record up to 5 days starting
at initiation of cytotoxic drugs administration. The daily
record contained the number of episodes of vomiting, the
0–100 scale of nausea visual analog scale (NVAS) and the
antiemetic therapy that was consumed over 5 days. Patients
were informed that an episode of vomiting that was
separated at least 1 min from the previous one counted as a
single episode (22).
STUDY OUTCOME DEFINITIONS
The primary outcome was acute nausea and vomiting which
was categorized based on the National Cancer Institute
Common Toxicity Criteria v.3 (NCI CTC v.3) (23). We
grouped the acute nausea and vomiting into Grade 1–2 and
Grade 3–4 nausea and vomiting. Patients were discharged
from the hospital on day 1, a few hours after the cytostatic
administration. Therefore, we could not categorize the sec-
ondary outcome based on the NCI CTC v.3. The secondary
outcome was delayed nausea and vomiting scored dichoto-
mic (yes or no). Patients without delayed emesis (no) were
defined as patients without vomiting and/or had ,5 score on
the NVAS scale, while patients with delayed emesis (yes)
were defined as patients with vomiting and/or scored 5
scale of NVAS (24,25).
SINGLE-NUCLEOTIDE POLYMORPHISM SELECTION
AND GENOTYPING ASSAYS
Three single-nucleotide polymorphisms (SNPs) in the
5-HT3B receptor gene: rs45460698 (deletion AAG in
50-UTR position), rs4938058 (intron) and rs7943062 (30 near
gene); three SNPs in the ABCB1 gene: rs1045642 (exon 26),
rs2032582 (exon 22) and rs1128503 (exon 12); and three
SNPs of CYP2D6; rs16947 (CYP2D6*2), rs3892097
(CYP2D6*4) and rs1065852 (CYP2D6*10) were selected
from the National Center for Biotechnology Information
SNP database. The selection of the SNPs was based on the
following criteria: a minor allele frequency of .0.2, a vali-
dated SNP according to the NCBI database, and preferably a
perfect linkage disequilibrium (LD) with other SNPs
(for 5-HTR3B receptor gene: D0- ¼ 1 and r2  0.7) and/or
indications for relevance based on previous publications
(18,26–29).
DNA was extracted from saliva samples. DNA was quanti-
fied using Nanodrop (Isogen, Maarssen, The Netherlands).
Genotypes were established using commercially available
pre-designed Taqman assays and analyzed on ABI 7500 real-
time PCR System from Applied Biosystems (Nieuwerkerk
aan den IJssel, The Netherlands) according to the manufac-
turer’ protocol of allelic discrimination. As a quality control,
at least 5% of samples were genotyped in duplicate and no
inconsistencies were found. The overall genotyping success
rate of the samples was more than 96%.
STATISTICAL METHODS
The genotype frequencies were assessed for deviations from
the Hardy–Weinberg equilibrium and they did not deviate
from the Hardy–Weinberg equilibrium. The gPlink software
was used to estimate the haplotype frequency and to set the
individual haplotypes from raw genotype data. The esti-
mation of haplotype frequencies/phases was 0.01 and
phase consideration was 0.01 (30).
The predicted phenotypes of SNPs in the CYP2D6 gene
were defined as follows: CYP26*2 is an active allele, *10 is
a decreased activity allele and *4 is a defective allele
(14,31,32). Therefore, the definitions of extensive metaboli-
zers (EMs) include *2/*2 and *2/*10; the intermediate meta-
bolizers (IMs) include *2/*4, *4/*10 and *10/*10; and poor
metabolizers (PMs) include *4/*4.
The x2 test was performed to test the association of
patient characteristics and primary and secondary outcome.
Moreover, the association of 5-HT3B receptor and
ABCB1 haplotypes and CYP2D6-predicted phenotypes with
primary and secondary outcome were analyzed by x2 test.
These associations are considered to be the result of
ondansetron as the antiemetic drug in the acute phase and
metoclopramide as the antiemetic drug in the delayed phase.
A P value of ,0.05 was considered as a significant associ-
ation. This study is explorative and hypothesis-generating,
and therefore, we decided not to correct for multiple testing.
RESULTS
A total of 202 patients were enrolled in this study. Table 1
presents the patient characteristics. The most frequent diag-
nosis was cervical cancer (59.9%), mostly diagnosed as
Stage 1 or 2 of cancer (68.8%). The majority of the patients
(90.6%) were treated with an intermediate dose of cisplatin
(50–70 mg/m2) either as monotherapy or in combination
therapy, and the remaining patients (9.4%) were treated with
cisplatin at a dosage of 75–100 mg/m2.
The presence of nausea and vomiting during the acute and
delayed phase is presented in Table 2. In the acute phase,
21.8% patients experienced acute nausea and 30.2% patients
experienced acute vomiting, whereas 38.6% patients experi-
enced nausea and/or vomiting in the delayed phase. Figures 1
and 2 present the means of vomiting episodes and NVAS
score over 5 days. The peak of vomiting episodes and NVAS
score was seen on day 2, with a gradual decline afterwards.
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Table 3 depicts the association between patient character-
istics and primary and secondary outcome measurements. No
significant associations of patient characteristics and primary
Figure 1. Mean (+SD) number of vomiting episodes over 5 days after
initiation of chemotherapy.
Figure 2. Mean (+SD) of nausea visual analog scale over 5 days after
initiation of chemotherapy.
Table 1. Characteristics of cancer patients treated with antiemetics
(n ¼ 202)
Characteristic n %
Age (mean+SD) 48.6+9.6
Gender
Male 14 6.9
Female 188 93.1
Diagnosis
Cervical cancer 121 59.9
Ovarian cancer 58 28.7
Lung cancer 3 1.6
Nasopharyngeal cancer 13 6.4
Vulva cancer 7 3.4
Stages of cancer
Stages I and II 139 68.8
Stages III and IV 63 31.2
Cytostatic agent
Cisplatin 81 40.1
Cisplatin and other agent 121 59.9
Cisplatin dose (mg/m2)
50–70 183 90.6
75–100 19 9.4
BMI
Underweight (16–18.5 kg/m2) 49 24.3
Normal (.18.5–25 kg/m2) 117 57.9
Overweight and obese (.25 kg/m2) 36 17.8
Karnofsky performance status
80–100% 182 90.1
50–70% 20 9.9
Co-morbidity
None 109 53.9
At least 1 93 46.1
History of motion sickness
Yes 39 19.3
No 163 80.7
History of morning sickness during pregnancy
Yes 45 22.3
No 134 66.3
Patients’ perception for having nausea and vomiting after chemotherapy
Yes 79 39.1
No 123 60.9
Anxiety
Yes 90 44.6
No 112 55.4
SD, standard deviation; BMI, body mass index; NA, not applicable because
patients have not been pregnant yet.
Table 2. The occurrence of acute and delayed chemotherapy-induced
nausea and vomiting
n %
Acute nausea
Grades 1 and 2 158 78.2
Grades 3 and 4 44 21.8
Acute vomiting
Grades 1 and 2 141 69.8
Grades 3 and 4 61 30.2
Delayed CINV
None 124 61.4
Yes 78 38.6
CINV, chemotherapy induced nausea and vomiting.
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Table 3. Univariate analysis of patient characteristics and primary secondary outcome
Patient characteristics Acute nausea [n (%)] P value Acute vomiting [n (%)] P value Delayed CINV [n (%)] P value
Grades 1 and 2
(n ¼ 158)
Grades 3 and 4
(n ¼ 44)
Grades 1 and 2
(n ¼ 141)
Grades 3 and 4
(n ¼ 61)
None
(n ¼ 78)
Yes
(n ¼ 124)
Age (mean + SD) 48.4 + 9.9 47.7 + 8.8 0.67 48.6 + 9.4 47.6 + 10.0 0.51 48.8 + 9.8 47.4 + 9.4 0.29
Gender
Male 12 (8.2) 1 (2.3) 0.20 10 (7.1) 3 (6.6) 0.75 115 (8.1) 74 (5.1) 0.55
Female 146 (91.8) 43 (97.7) 131 (92.9) 58 (93.4) 9 (91.9) 4 (94.9)
Diagnosis
Cervical cancer 95 (60.1) 26 (59.1) 0.86 88 (62.4) 33 (54.1) 0.46 79 (63.7) 42 (53.8) 0.31
Ovarian cancer 46 (29.1) 12 (27.3) 39 (27.7) 19 (31.1) 41 (25.0) 27 (34.6)
Others 17 (10.8) 6 (13.6) 14 (9.9) 9 (14.8) 13 (11.3) 9 (11.5)
Stage of cancer
Stages I and II 106 (67.1) 33 (75.0) 0.32 94 (66.7) 45 (73.8) 0.32 86 (69.4) 53 (67.9) 0.83
Stages III and IV 52 (32.9) 11 (25.0) 47 (33.3) 16 (26.2) 38 (30.6) 25 (32.1)
Cytostatic agent
Cisplatin 59 (37.3) 22 (50.5) 0.13 56 (39.7) 25 (41.0) 0.87 53 (42.7) 28 (35.9) 0.33
Cisplatin þ other agents 99 (62.7) 22 (50.0) 85 (60.3) 36 (59.0) 71 (57.3) 50 (64.1)
Cisplatin dose
,50–70 mg/m2 143 (90.5) 40 (90.9) 0.93 130 (92.2) 53 (86.9) 0.24 114 (91.9) 69 (88.5) 0.41
75–100 mg/m2 15 (9.5) 4 (9.1) 11 (7.8) 8 (13.1) 10 (8.1) 9 (11.5)
BMI
Underweight (,16 kg/m2) 42 (26.6) 7 (15.9) 0.16 38 (27.0) 11 (18.0) 0.05 27 (21.8) 22 (28.2) 0.15
Normal (16–18.5 kg/m2) 86 (54.4) 31 (70.5) 74 (52.5) 43 (70.5) 70 (56.5) 47 (50.3)
Overweight and Obese
(.18.5 kg/m2)
30 (19.0) 6 (13.6) 29 (20.6 7 (11.5) 27 (21.8) 89 (11.5)
Karnofsky performance status
80–100% 143 (90.5) 39 (88.6) 0.71 129 (91.5) 53 (86.9) 0.95 113 (91.1) 69 (88.5) 0.54
50–70% 15 (9.5) 5 (11.4) 12 (8.5) 8 (13.1) 11 (8.9) 9 (11.5)
Co-morbidity
None 83 (52.5) 26 (59.1) 0.44 74 (52.5) 35 (57.4) 0.52 70 (66.9) 39 (50.0) 0.37
At least 1 75 (47.5) 18 (40.9) 67 (47.5) 26 (42.6) 54 (33.1) 39 (50.0)
Motion sickness history
No 131 (82.9) 32 (72.7) 0.13 119 (84.4) 44 (72.1) 0.09 103 (83.1) 60 (76.9) 0.28
Yes 27 (17.1) 12 (27.3) 22 (15.6) 17 (27.9) 21 (16.9) 18 (23.1)
Morning sickness history
No 106 (67.1) 28 (63.6) 0.23 99 (70.2) 35 (57.4) 0.13 84 (67.7) 50 (64.1) 0.27
Yes 32 (20.3) 13 (29.5) 27 (19.1) 18 (29.5) 21 (19.4) 21 (26.9)
NA 20 (12.7) 3 (6.8) 15 (10.6) 8 (13.1) 16 (12.9) 7 (9.0)
Patients’ perception for NV after chemotherapy
No 97 (61.4) 26 (59.1) 0.78 91 (64.5) 32 (52.5) 0.11 74 (59.7) 49 (62.8) 0.66
Yes 61 (38.6) 18 (40.9) 50 (35.5) 29 (47.5) 50 (40.3) 29 (37.2)
Anxiety
No 84 (53.2) 28 (63.6) 0.21 77 (54.6) 35 (57.4) 0.72 68 (54.8) 44 (56.4) 0.83
Yes 74 (46.8) 16 (36.4) 64 (45.4) 26 (42.6) 56 (45.2) 34 (43.6)
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or secondary endpoint were found. However, the data suggest
that Grade 3 and 4 acute CINV and delayed CINV are more
frequent in younger patients with low performance and a
history of motion sickness but the associations did not reach
significance. The statistical analyses were performed in the
female subjects to understand the association between gene
variants, patients’ characteristic and the primary/secondary
outcome. However, we found no significant association in the
analysis results (data not shown).
In Table 4, the association of gene haplotypes and pheno-
types with primary and secondary endpoint are presented. A
statistical significant association was found between the CTG
haplotype in the ABCB1 gene and the presence of nausea
and vomiting in the delayed phase. Carriers of the ABCB1
CTG haplotype experienced more frequent Grade 3/4 CINV
compared with the other haplotypes (P, 0.05). Multivariate
analysis demonstrated that age and gender did not alter this
result (data not shown).
Table 4. Univariate analysis of gene haplotypes and primary–secondary outcome
Gene Acute nausea [n (%)] P value Acute vomiting [n (%)] P value Delayed CINV
[n (%)]
P value
Grades 1 and 2 Grades 3 and 4 Grades 1 and 2 Grades 3 and 4 None Yes
ABCB1 gene n ¼ 150 n ¼ 38 n ¼ 136 n ¼ 52 n ¼ 119 n ¼ 69
CCG
Other haplotypes 87 (58.0) 23 (60.5) 0.78 82 (60.3) 28 (53.8) 0.42 67 (56.3) 43 (62.3) 0.42
Carrier of CCG haplotype 63 (42.0) 15 (39.5) 54 (39.7) 24 (46.2) 52 (43.7) 26 (37.3)
CTG
Other haplotypes 76 (50.7) 22 (57.9) 0.43 68 (50.0) 30 (57.7) 0.35 70 (58.8) 28 (40.6) 0.02a
Carrier of CTG haplotype 74 (49.3) 16 (42.1) 68 (50.0) 22 (42.3) 49 (41.2) 41 (59.4)
CTT
Other haplotypes 138 (92.0) 38 (100.0) 0.07 125 (91.9) 51 (98.1) 0.12 109 (91.6) 67 (97.1) 0.14
Carrier of CTT haplotype 12 (8.0) 0 (0.0) 11 (8.1) 1 (1.9) 10 (8.4) 2 (2.9)
TTT
Other haplotypes 60 (40.0) 12 (31.6) 0.34 53 (39.0) 19 (36.5) 0.76 46 (38.7) 26 (37.7) 0.90
Carrier of TTT haplotype 90 (60.0) 26 (68.4) 83 (61.0) 33 (63.5) 73 (61.3) 43 (62.3)
5HT3B gene n ¼ 150 n ¼ 36 n ¼ 131 n ¼ 55
AAGAG
Other haplotypes 34 (22.7) 10 (27.8) 0.52 32 (24.4) 12 (21.8) 0.70
Carrier of AAGAG haplotype 116 (77.3) 26 (72.2) 99 (75.6) 43 (78.2)
AAGGG
Other haplotypes 106 (70.7) 21 (58.3) 0.15 87 (66.4) 40 (72.7) 0.40
Carrier of AAGGG haplotype 44 (29.3) 15 (41.7) 44 (33.6) 15 (27.3)
AAGAA
Other haplotypes 112 (74.7) 30 (83.3) 0.28 99 (75.6) 43 (78.2) 0.70
Carrier of AAGAA haplotype 38 (25.3) 6 (16.7) 32 (24.4) 12 (21.8)
Del AG
Other haplotypes 107 (71.3) 26 (72.2) 0.92 96 (73.3) 37 (67.3) 0.41
Carrier of del AG haplotype 43 (28.7) 10 (27.8) 35 (26.7) 18 (32.7)
CYP2D6-predicted phenotype n ¼ 150 n ¼ 37 n ¼ 133 n ¼ 54 n ¼ 117 n ¼ 70
EM 93 (62.0) 28 (75.7) 0.12 86 (64.7) 35 (64.8) 0.98 76 (65.0) 45 (64.3) 0.93
IM 57 (38.0) 9 (24.3) 47 (35.3) 19 (35.2) 41 (35.0) 25 (35.7)
EM, extensive metabolizers; IM, intermediate metabolizers.
aSignificant value.
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In our population, no predicted phenotypes of CYP2D6,
the UMs or PMs were found; the percentages of EMs and
IMs were 59.9 and 32.7%, respectively.
DISCUSSION
Our study confirms that prevention of CINV is suboptimal,
and ondansetron and dexamethasone could prevent 80% of
the patients from acute nausea and 70% of the patients from
acute vomiting. In the delayed phase, with metoclopramide,
60% of the patients experienced no nausea and/or vomiting.
These percentages are lower than commonly seen with
newer antiemetic drugs such as aprepitant or with the use of
5HT3RAs for prevention during the delayed phase, but these
are no standard therapies in Indonesia.
To date, the reasons of variability in antiemetic drug
response are largely unknown. To some extent, patient charac-
teristic such as age and gender may contribute to variable
drug response. Although we did not find significant associ-
ation between patient characteristic and primary or secondary
outcome in this study, a non-significant trend analysis sup-
ported that young patients were more susceptible to experi-
ence higher grade of acute and delayed nausea and vomiting.
A previous study in cancer patients showed that female
gender and younger age were associated with higher risk of
CINV (9). A reason for not replicating these findings in our
study is that our patients were mostly women, of relatively
young age and with a narrow distribution of age, resulting in
limited power to find associations with gender and age.
Remarkably, patient-related risk factors such as age play no
role in individualizing choice of antiemetic treatment in
patients treated with highly emetogenic chemotherapy (33).
Variations in genes which are involved in the pharmacology
of antiemetic drugs may explain interpatient variability in
response to these drugs. Indeed, our study shows that carrier-
ship of the CTG haplotype in the ABCB1 gene increases the
risk of delayed CINV and may therefore modify the effect of
metoclopramide. In contrast, our study shows that genetic var-
iants in ABCB1, 5-HT3B receptor and CYP2D6 are not related
to ondansetron efficacy in acute CINV.
Interestingly, while the CTG haplotype of ABCB1 is
related to delayed CINV, it is not related to acute CINV.
This could be explained by the mechanism of cisplatin-
induced nausea and vomiting which is probably mostly
mediated by the serotonin release in the gastrointestinal
enterochromaffin cells and not in the central nervous system
(34). Thus, the haplotype of ABCB1 which could theoreti-
cally increase the amount of ondansetron that crosses the
blood–brain barrier did not show significant impact in the
ondansetron response. However, in a previous pharmacoge-
netic study in Caucasian cancer patients, it was shown that
the TT genotype of 3435C.T of ABCB1 experienced less
severe of emesis, because it was supposed that higher con-
centrations of ondansetron were available in the central
nervous system (13).
The significant association between the carrier of the CTG
haplotype in the ABCB1 gene and delayed nausea vomiting
indicates that metoclopramide efficacy is modified by the
ABCB1 gene variation. The proposed mechanism is that
passage of metoclopramide across the blood–brain barrier is
increased in the absence of an active P-gP. Indeed, metoclo-
pramide’s site of action as an antiemetic is thought to be in
the fourth ventricle, which is located behind the blood–brain
barrier. The role of P-gP in metoclopramide transport in the
central nervous system is consistent with the finding of and
increased metoclopramide concentration in the central
nervous system in patients with an inactive P-gP leading to
extra pyramidal symptoms (19).
In the current study, the percentage of patients who experi-
enced acute nausea and vomiting seemed to be higher in car-
riers of the AAGAG haplotype in the 5-HT3B receptor gene,
although it did not reach statistical significance. Patients car-
rying the deletion AAG haplotype in the 5-HT3B receptor
experienced a lower grade of nausea and a higher grade of
vomiting in the acute phase compared with the other
haplotypes.
We performed a haplotype analysis because we could con-
sider information about human evolutionary history and
genetic variants by finding the LD (35). Previous studies in
Caucasian cancer patients used the genotype of 3435C.T of
the ABCB1 gene and the -100_-102 AAG deletion variant of
the 5-HTR3B gene and performed an association analysis
rather than a haplotype analysis (13,18). Therefore, we
cannot compare our study findings with the previous studies
in Caucasian cancer patients. Teh et al. reported that the
allele frequencies in 3435C.T of the ABCB1 gene were
different between Asians and Caucasians.
Among our patients, no predicted phenotypes of CYP2D6
PMs or UMs were identified and the frequency of EMs
exceeded that of IMs. Similar results were found in a previous
study in healthy subjects of Malaysian Chinese origin, pre-
senting that there were no PM and the frequency of EM in
this population was also around 60% (31). Indeed, in subjects
of Asian origin, the PM phenotype is very rare. The previous
study of Kaiser et al. in Caucasian cancer patients showed
that a different antiemetic response to ondansetron was found
in both CYP2D6 UMs and PMs. The PMs and UMs showed
the lowest and the highest score of nausea and vomiting in the
acute phase, respectively (14). Since the incidence of pre-
dicted phenotypes of CYP2D6 PMs and UMs in subjects with
Indonesian origin is very low, the role of the CYP2D6 pheno-
type in explaining variability in ondansetron and metoclopra-
mide efficacy in Asians seems to be limited if present at all.
While there are two reports suggesting that CYP2D6 has a
significant role in metoclopramide metabolism (20,21), we
found no association between CYP2D6-predicted phenotype
and metoclopramide efficacy. The EMs and IMs as the only
predicted phenotypes found in our study may be the reasons
for these results.
In conclusion, our study suggests that the carriers of the
CTG haplotype of the ABCB1 gene have increased risk of
Jpn J Clin Oncol 2011 Page 7 of 9
CINV during the delayed phase. However, variants in the
genes encoding ABCB1, CYP2D6 and 5-HT3B receptor are
not associated with antiemetic efficacy of ondansetron in
Asian cancer patients during the acute phase. Further studies
are needed to confirm the application of these results in
clinical practice.
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